– Seeking inclusion of CV risk reduction indications in Europe – – Anticipated approvals in Europe in the first half of 2024 – ANN ARBOR, Mich., June 28, 2023 (GLOBE NEWSWIRE) Esperion (NASDAQ: ESPR) to.
Jayesh Desai, MBBS, FRACP, reports prior phase 1 data on the use of divarasib monotherapy in KRAS G12C–mutated CRC and early efficacy, safety, and presents pharmacokinetic data from the use of divarasib plus cetuximab from a phase 1 trial.
Esperion (NASDAQ: ESPR) reported a net loss of $61.7 million for the first quarter of 2023 on revenue of $24.3 million, compared to a net loss of $56.7 million on revenue of $18.8 million during the same quarter a year ago.
The selective, oral KRASG12C inhibitor divarasib demonstrated promising clinical activity in patients with colorectal cancer treated with the agent plus cetuximab.
Only days after its European licensor refused to make good on $300 million in milestone payments, Ann Arbor drugmaker Esperion announced a $56.7 million stock sale to raise cash.
Esperion announced Monday it sold roughly 33.2 million shares and short-term warrants at $1.675 and $1.55 per share,…